Q-S Ng1, H Mandeville2, V Goh3, R Alonzi2, J Milner2, D Carnell2, K Meer2, A R Padhani3, M I Saunders2, P J Hoskin4. 1. Mount Vernon Cancer Centre, Northwood, Middlesex, UK; Department of Medical Oncology, National Cancer Centre Singapore, Singapore. 2. Mount Vernon Cancer Centre, Northwood, Middlesex, UK. 3. Paul Strickland Scanner Centre, Mount Vernon Hospital, Northwood, Middlesex, UK. 4. Mount Vernon Cancer Centre, Northwood, Middlesex, UK. Electronic address: peterhoskin@nhs.net.
Abstract
BACKGROUND: The vascular disrupting agent combretastatin-A4-phosphate (CA4P) demonstrated antitumour activity in preclinical studies when combined with radiation. METHODS: Patients with non-small-cell lung cancer (NSCLC), prostate adenocarcinoma, and squamous cell carcinoma of the head and neck (SCCHN) received 27 Gy in 6 fractions treating twice weekly over 3 weeks, 55 Gy in 20 fractions over 4 weeks, and 66 Gy in 33 fractions over 6 weeks respectively. CA4P was escalated from 50 mg/m2 to 63 mg/m2. CA4P exposure was further increased from one to three to six doses. Patients with SCCHN received cetuximab in addition. RESULTS: Thirty-nine patients received 121 doses of CA4P. Dose-limiting toxic effects (DLTs) of reversible ataxia and oculomotor nerve palsy occurred in two patients with prostate cancer receiving weekly CA4P at 63 mg/m2. DLT of cardiac ischaemia occurred in two patients with SCCHN at a weekly dose of 50 mg/m2 in combination with cetuximab. Three patients developed grade 3 hypertension. Responses were seen in 7 of 18 patients with NSCLC. At 3 years, 3 of 18 patients with prostate cancer had prostate-specific antigen relapse. CONCLUSIONS: Radiotherapy with CA4P appears well tolerated in most patients. The combination of CA4P, cetuximab, and radiotherapy needs further scrutiny before it can be recommended for clinical studies.
BACKGROUND: The vascular disrupting agent combretastatin-A4-phosphate (CA4P) demonstrated antitumour activity in preclinical studies when combined with radiation. METHODS: Patients with non-small-cell lung cancer (NSCLC), prostate adenocarcinoma, and squamous cell carcinoma of the head and neck (SCCHN) received 27 Gy in 6 fractions treating twice weekly over 3 weeks, 55 Gy in 20 fractions over 4 weeks, and 66 Gy in 33 fractions over 6 weeks respectively. CA4P was escalated from 50 mg/m2 to 63 mg/m2. CA4P exposure was further increased from one to three to six doses. Patients with SCCHN received cetuximab in addition. RESULTS: Thirty-nine patients received 121 doses of CA4P. Dose-limiting toxic effects (DLTs) of reversible ataxia and oculomotor nerve palsy occurred in two patients with prostate cancer receiving weekly CA4P at 63 mg/m2. DLT of cardiac ischaemia occurred in two patients with SCCHN at a weekly dose of 50 mg/m2 in combination with cetuximab. Three patients developed grade 3 hypertension. Responses were seen in 7 of 18 patients with NSCLC. At 3 years, 3 of 18 patients with prostate cancer had prostate-specific antigen relapse. CONCLUSIONS: Radiotherapy with CA4P appears well tolerated in most patients. The combination of CA4P, cetuximab, and radiotherapy needs further scrutiny before it can be recommended for clinical studies.
Authors: Ravi Kumar Vyas Devambatla; Wei Li; Nilesh Zaware; Shruti Choudhary; Ernest Hamel; Susan L Mooberry; Aleem Gangjee Journal: Bioorg Med Chem Lett Date: 2017-05-27 Impact factor: 2.823
Authors: Chien-Ming Li; Yan Lu; Jianjun Chen; Terrence A Costello; Ramesh Narayanan; Mara N Dalton; Linda M Snyder; Sunjoo Ahn; Wei Li; Duane D Miller; James T Dalton Journal: Pharm Res Date: 2012-07-04 Impact factor: 4.200
Authors: Ravi Kumar Vyas Devambatla; Ojas A Namjoshi; Shruti Choudhary; Ernest Hamel; Corena V Shaffer; Cristina C Rohena; Susan L Mooberry; Aleem Gangjee Journal: J Med Chem Date: 2016-06-07 Impact factor: 7.446
Authors: Tarun Ojha; Vertika Pathak; Yang Shi; Wim E Hennink; Chrit T W Moonen; Gert Storm; Fabian Kiessling; Twan Lammers Journal: Adv Drug Deliv Rev Date: 2017-07-08 Impact factor: 15.470